Skip to Content

Rebus Hldgs Inc RBSH

Morningstar Rating
$0.00 0.00 (0.00%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

RBSH is trading at a 697% premium.
Price
$0.00
Fair Value
$1.19
Uncertainty
Extreme
1-Star Price
$2.97
5-Star Price
$8.73
Economic Moat
Fxmz
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if RBSH is a good fit for your portfolio.

Trading Information

Previous Close Price
$0.00
Day Range
$0.000.01
52-Week Range
$0.000.02
Bid/Ask
$0.00 / $0.00
Market Cap
$3,213.29
Volume/Avg
10,191 / 112,626

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Rebus Hldgs Inc is an early-stage, pre-revenue, pharmaceutical company that is focused on the development of prodrug cancer therapeutics for the treatment of disease. The company along with its subsidiaries is engaged in the production of small-molecule adenosine receptor modulators. Adenosine is an extracellular signaling molecule that regulates multiple aspects of tissue function and specifically plays a role in immunity and inflammation.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Total Number of Employees

Valuation

Metric
RBSH
Price/Earnings (Normalized)
Price/Book Value
Price/Sales
Price/Cash Flow
Price/Earnings
RBSH

Financial Strength

Metric
RBSH
Quick Ratio
0.00
Current Ratio
0.00
Interest Coverage
25.78
Quick Ratio
RBSH

Profitability

Metric
RBSH
Return on Assets (Normalized)
−564.59%
Return on Equity (Normalized)
Return on Invested Capital (Normalized)
Return on Assets
RBSH
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk A/S ADR
NVO
BlgnxpfpWrsx$636.2 Bil
Vertex Pharmaceuticals Inc
VRTX
YclwdqgvZgllqk$126.1 Bil
Regeneron Pharmaceuticals Inc
REGN
ZchzzshwKbntj$121.2 Bil
Moderna Inc
MRNA
KcwkvpfrBmvx$46.5 Bil
Alnylam Pharmaceuticals Inc
ALNY
FkfrpwdvKhyfwq$33.0 Bil
argenx SE ADR
ARGX
WqjjzlkTzxd$27.9 Bil
BioNTech SE ADR
BNTX
SlcxkqdQfg$20.5 Bil
Biomarin Pharmaceutical Inc
BMRN
KdjjcjdhkGxnbdsb$16.1 Bil
United Therapeutics Corp
UTHR
LbbhqbstTdlf$14.3 Bil
Incyte Corp
INCY
QrtblvznGhgrsf$12.5 Bil

Sponsor Center